INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 143 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,773,616 | -54.3% | 69,698 | -53.8% | 0.00% | -66.7% |
| Q1 2024 | $10,445,740 | +94.6% | 150,950 | +101.4% | 0.00% | +50.0% |
| Q4 2023 | $5,366,630 | +18.1% | 74,932 | -14.1% | 0.00% | +100.0% |
| Q3 2023 | $4,543,551 | +43.5% | 87,225 | +74.5% | 0.00% | 0.0% |
| Q2 2023 | $3,165,367 | -81.7% | 49,990 | -84.3% | 0.00% | -83.3% |
| Q1 2023 | $17,265,674 | +62461.3% | 318,849 | -38.9% | 0.01% | -25.0% |
| Q4 2022 | $27,598 | -99.9% | 521,502 | -28.6% | 0.01% | -38.5% |
| Q3 2022 | $34,005,000 | -21.0% | 730,882 | -3.0% | 0.01% | -13.3% |
| Q2 2022 | $43,026,000 | -5.6% | 753,768 | +1.2% | 0.02% | +7.1% |
| Q1 2022 | $45,577,000 | +10.3% | 744,880 | -5.7% | 0.01% | +16.7% |
| Q4 2021 | $41,338,000 | +51.6% | 789,819 | +8.0% | 0.01% | +33.3% |
| Q3 2021 | $27,267,000 | +10.0% | 731,479 | +20.4% | 0.01% | +12.5% |
| Q2 2021 | $24,794,000 | -6.7% | 607,434 | -22.4% | 0.01% | -11.1% |
| Q1 2021 | $26,567,000 | -29.1% | 783,031 | -33.5% | 0.01% | -35.7% |
| Q4 2020 | $37,454,000 | -5.7% | 1,177,771 | -23.9% | 0.01% | -17.6% |
| Q3 2020 | $39,725,000 | -3.2% | 1,548,152 | -3.2% | 0.02% | -5.6% |
| Q2 2020 | $41,058,000 | +63.4% | 1,599,493 | -2.2% | 0.02% | +38.5% |
| Q1 2020 | $25,130,000 | -56.9% | 1,634,982 | -3.9% | 0.01% | -38.1% |
| Q4 2019 | $58,373,000 | +344.4% | 1,701,373 | -3.2% | 0.02% | +320.0% |
| Q3 2019 | $13,135,000 | -40.8% | 1,758,347 | +2.9% | 0.01% | -44.4% |
| Q2 2019 | $22,189,000 | +12.2% | 1,709,500 | +5.3% | 0.01% | +12.5% |
| Q1 2019 | $19,771,000 | +20.2% | 1,623,196 | +12.4% | 0.01% | +14.3% |
| Q4 2018 | $16,450,000 | -46.6% | 1,444,223 | +1.7% | 0.01% | -41.7% |
| Q3 2018 | $30,813,000 | +28.5% | 1,419,888 | +4.7% | 0.01% | +20.0% |
| Q2 2018 | $23,974,000 | -4.8% | 1,356,720 | +13.4% | 0.01% | 0.0% |
| Q1 2018 | $25,194,000 | +35.7% | 1,196,860 | -6.6% | 0.01% | +25.0% |
| Q4 2017 | $18,563,000 | +25.3% | 1,281,975 | +36.5% | 0.01% | +33.3% |
| Q3 2017 | $14,817,000 | +84.3% | 938,980 | +45.1% | 0.01% | +50.0% |
| Q2 2017 | $8,038,000 | +296.9% | 647,187 | +419.3% | 0.00% | +300.0% |
| Q1 2017 | $2,025,000 | +214.4% | 124,622 | +192.2% | 0.00% | – |
| Q4 2016 | $644,000 | – | 42,653 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |